Indeed, widespread “adaptive kinome reprogramming” in response to chronic Her2 inhibition has been reported to upregulate a variety of compensatory receptor tyrosine kinases, each with the demonstrated ability to independently activate the downstream oncogenic pathways (mainly PI3K/mTOR) and tumor growth [37]. This evidence concerns the gene ERBB2 and neoplasm.